CHMP rejects AB Science’s ALS drug
AB Science’s share price has taken a hit after European Medicine Agency’s advisors rejected approval of masitinib for amyotrophic lateral sclerosis.
Read More
Tag: Lou Gehrig
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
